![Diana Brainard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Diana Brainard
Directeur/Membre du Conseil chez
NEKTAR THERAPEUTICS
Fortune : 132 918 $ au 30/06/2026
Profil
Diana M.
Brainard is currently an Independent Director at Nektar Therapeutics since 2021 and an Independent Director at Affinia Therapeutics, Inc. since 2022.
Formerly, served as Chief Executive Officer & Director at AlloVir, Inc. from 2021 to 2024, Senior VP-HIV & Emerging Viral Infections at Gilead Sciences, Inc. from 2018 to 2021, and Partner at MPM BioImpact LLC.
Education includes an undergraduate degree from Brown University in 1992 and a doctorate from Tulane University School of Medicine in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NEKTAR THERAPEUTICS 0,01 % | 06/04/2026 | 1 904 ( 0,01 % ) | 132 918 $ | 30/06/2026 |
Postes actifs de Diana Brainard
| Sociétés | Poste | Début |
|---|---|---|
| NEKTAR THERAPEUTICS | Directeur/Membre du Conseil | 11/11/2021 |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Directeur/Membre du Conseil | 08/03/2022 |
Anciens postes connus de Diana Brainard
| Sociétés | Poste | Fin |
|---|---|---|
| ALLOVIRPAR | Directeur Général | 19/12/2024 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2021 |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Private Equity Investor | - |
Formation de Diana Brainard
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
64
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Tulane University School of Medicine
 Tulane University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AlloVir, Inc.
 AlloVir, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for severe infections | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Health Technology |
